OncoTargets and Therapy

Targeting hedgehog signaling in cancer: research and clinical developments

Abstract: Since its first description in Drosophila by Drs Nusslein-Volhard and Wieschaus in 1980, hedgehog (Hh) signaling has been implicated in regulation of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of Gorlin syndrome in 1996 by two independent teams. Later, it was shown that Hh signaling may be involved in many types of cancer, including skin, leukemia, lung, brain, and gastrointestinal cancers. In early 2012, the US Food and Drug Administration approved the clinical use of Hh inhibitor Erivedge/vismodegib for treatment of locally advanced and metastatic basal cell carcinomas. With further investigation, it is possible to see more clinical applications of Hh signaling inhibitors. In this review, we will summarize major advances in the last 3 years in our understanding of Hh signaling activation in human cancer, and recent developments in preclinical and clinical studies using Hh signaling inhibitors.

Keywords: hedgehog, smoothened, PTCH1, cancer, signal transduction, clinical trials, animal model

Introduction

Remarkable progress has been made since the hedgehog (Hh) mutant phenotype was first described in fruit fly in 1980.1 Three vertebrate homologues of Hh and their receptors were identified in the 1990s.2-6 As an essential pathway during development, the Hh pathway is critical for maintaining tissue polarity and stem cell population. The first link between Hh signaling and cancer was shown in tumor-prone Gorlin syndrome in 1996.7-11 In early 2012, Hh signaling inhibitor GDC-0449 (Erivedge/vismodegib; Hoffmann-La Roche Ltd, Basel, Switzerland) was approved by the US Food and Drug Administration for treatment of locally advanced and metastatic basal cell carcinomas (BCCs).

The general signaling mechanisms of the Hh pathway are conserved from flies to humans.12 Mammalian Hh signaling molecules include ligands (sonic Hh, Indian Hh, and desert Hh), patched receptors (PTCH1, PTCH2), signal transducer smoothened (SMO), and transcription factors (Gli1, Gli2, Gli3) (see Figure 1). In the absence of ligands, SMO serves as the key signal transducer, whose function is inhibited by another transmembrane protein patched (PTCH1). Upon binding of an active Hh ligand, this inhibition is released, allowing SMO to signal downstream, eventually leading to activation of Gli transcription factors. Gli molecules can bind the specific consensus sequences located in the promoter region of the target genes to regulate target gene expression.13,14
In the last 3 years, there has been significant progress regarding Hh signaling and its significance in cancer development and therapeutics. The total number of publications on Hh signaling in the last 3 years is close to 30% of all Hh-related publications, and progress has been made in the following areas: 1) better understanding of Hh signal transduction and the associated target genes, 2) more reliable mouse models linking Hh signaling to human malignancies, 3) better understanding of Hh signaling mechanisms during cancer development and metastasis, 4) an increasing number of clinical and preclinical studies on cancer treatment using Hh signaling inhibitors, and 5) emerging evidence of Hh signaling in supporting residual cancer cells and cancer stem cells.

Signal transduction of the Hh pathway

All Hh proteins are secreted molecules, functioning at short range on nearby cells or at long range to distant cells during development.15–17 Hh protein precursors undergo post-translational modifications (autocleavage to release the N-terminal fragment [HhN], covalently binding to a cholesterol moiety at the C-terminal end, and palmitoylation by a palmitoylacyltransferase at the N-terminus of HhN).18–21 Molecules involved in Hh protein transport and distribution include the transmembrane transporter-like protein dispatched (Disp),22–24 metalloproteinases,25 the heparan sulfate proteoglycans Dally-like (Dlp) and Dally26,27 or their regulators,28 as well as enzymes such as sulfatase and tutevu.29–31

Figure 1 A diagram of hedgehog (Hh) signaling in mammalian cells. Smoothened (SMO) is the key signal transducer of the Hh pathway. In the absence of the Hh ligands, SMO receptor patched (PTC) is thought to be localized in the cilium to inhibit SMO signaling. Coreceptors of Hh include CDD (cell adhesion molecule-related/downregulated by oncogenes), brother of CDD (BOC), Gas1, glypican 3 (GPC3), and GPC5. Wnt inhibitory factor-1 (WIF1) can also regulate Hh signaling through association with CDD, BOC, or GPC5. Gli molecules are processed with the help of suppressor of fused (SuFu)/KIF7, β-TRCP molecules into repressor forms, which turn off the Hh signaling pathway. Other negative regulators of Gli molecules include Rab23, protein kinase A (PKA), SuFu, tumor suppressor sucrose nonfermenting 5 (SNF5), Cullin 3 (Cul3), and itchy E3 ubiquitin ligase (Itch) through regulation Gli protein modifications, nuclear–cytoplasm shuttling, as well as transcriptional activities. In the presence of Hh, PTC is thought to be shuttled out of cilium and is unable to inhibit SMO. The ciliary localization of SMO is thought to require β-arrestin 2 (βAR2), and G protein coupled receptor kinase 2 (GRK2). Hh receptor promotes SMO conformational changes to form dimers. Gli molecules are now processed to active forms (GliA), which will activate the Hh target genes. This process can be inhibited by KIF7 and SuFu. Protein kinase C isoform i/l (PKCι/λ) is known to positively regulate Gli transcriptional activity. Positive regulators are in red, negative regulators are in blue, and target genes are in pink. KIF7 can function (in black) as a negative regulator or a positive regulator. The interacting pathways with the Hh pathway are in green. Although the role of cilium for Hh signaling during embryonic development is well established, cancer cells generally lack cilia. It has been demonstrated that lack of cilia prevents development of basal cell carcinomas in mice. It is not clear whether this is true for all other types of Hh signaling-associated cancer.

Abbreviations: EGF, epidermal growth factor; EMT, epithelial–mesenchymal transition; IGf, insulin-like growth factor; PDGF, platelet-derived growth factor; TGFβ, transforming growth factor β; VEGF, vascular endothelial growth factor; GDC0449, synthetic small molecules targeting at SMO signaling; BMS833932, synthetic small molecules targeting at SMO signaling; LY2940680 synthetic small molecules targeting at SMO signaling; SAG, smoothened agonist; MDM2, Mouse double minute 2 homolog; P53, p53 tumor suppressor; TGFβ, transforming growth factor β; BCL2, B-cell lymphoma 2; bTRCP, beta-transducin repeat containing protein; STAT3, signal transducer and activator of transcription 3; AKT, homolog of viral oncogene v-AKT; MEK, MAPK or eRK kinase; PI3K, Phosphatidylinositide 3-kinases; CDD, cell adhesion molecule-related/downregulated by oncogenes; brother of CDD (BOC); Gas1, glypican 3 (GPC3); and GPC5. wnt inhibitory factor-1 (WIF1) can also regulate Hh signaling through association with CDD, BOC, or GPC5. Gli molecules are processed with the help of suppressor of fused (SuFu)/KIF7, β-TRCP molecules into repressor forms, which turn off the Hh signaling pathway. Other negative regulators of Gli molecules include Rab23, protein kinase A (PKA), SuFu, tumor suppressor sucrose nonfermenting 5 (SNF5), Cullin 3 (Cul3), and itchy E3 ubiquitin ligase (Itch) through regulation Gli protein modifications, nuclear–cytoplasm shuttling, as well as transcriptional activities. In the presence of Hh, PTC is thought to be shuttled out of cilium and is unable to inhibit SMO. The ciliary localization of SMO is thought to require β-arrestin 2 (βAR2), and G protein coupled receptor kinase 2 (GRK2). Hh receptor promotes SMO conformational changes to form dimers. Gli molecules are now processed to active forms (GliA), which will activate the Hh target genes. This process can be inhibited by KIF7 and SuFu. Protein kinase C isoform i/l (PKCι/λ) is known to positively regulate Gli transcriptional activity. Positive regulators are in red, negative regulators are in blue, and target genes are in pink. KIF7 can function (in black) as a negative regulator or a positive regulator. The interacting pathways with the Hh pathway are in green. Although the role of cilium for Hh signaling during embryonic development is well established, cancer cells generally lack cilia. It has been demonstrated that lack of cilia prevents development of basal cell carcinomas in mice. It is not clear whether this is true for all other types of Hh signaling-associated cancer.
Figure 1 shows the mammalian Hh signaling pathway with major players in the diagram. Several molecules are engaged in reception of Hh ligands, with patched (PTC, one PTC in fly, and two PTCs in vertebrates: PTCH1 and PTCH2) as the major receptor. Studies from cultured cells indicate that PTC inhibits SMO at a substoichiometric concentration. Hh-interacting protein (HIP) can compete with PTC on Hh binding, resulting in negative regulation of Hh signaling. On the other hand, interference Hh or its vertebrate homologues cell adhesion molecule related/downregulated by oncogenes (CDO) and BOC (brother of CDO), GAS1, and glypican-3 (GPC3) serve as coreceptors of Hh. In contrast to the inhibitory effect of glypican-3, glypican-5 (GPC5) and other heparan sulfate proteoglycans are shown to stimulate Hh signaling by promoting binding of sonic Hh to PTCH1. The effect of GPC5 and interference Hh homologues requires another secreted extracellular molecule: Wnt inhibitory factor-1 (WIF1). It is still not entirely clear how binding of Hh proteins results in the pathway activation. It is proposed that PTC limits SMO signaling via transporting endogenous small molecules specifically targeted to SMO. Candidates of these small molecules include PI4P, lipoproteins, and provitamin D3. It is currently not very clear how these molecules regulate SMO signaling.

It is now known that glucocorticoid molecules can modulate SMO signaling through regulating its ciliary localization. Several recent reports support SMO to G protein coupling, but the physiological relevance of the G protein coupling of SMO in carcinogenesis has not been convincingly demonstrated. G0 can also regulate Gli proteins independent of SMO. It is quite clear that two important events occur during SMO signaling in mammalian cells. First, SMO protein undergoes conformational change to favor SMO signaling, although the regulatory mechanism underlying this conformational change is not clear. Second, ciliary translocation of mammalian SMO protein is critical for Hh signaling. Several reports now link neureilin 1/2 (Nrp1/2) to SMO signaling. Several molecules are identified to be genetically downstream of SMO in Drosophila, including COS2, suppressor of fused (SuFu), and fused. A COS2 homologue, kinesin like-protein KIF7, functions in the Hh pathway but not directly associated with SMO suggesting that KIF7 does not contain all COS2 functions in vertebrates. In contrast, the phenotype of fused mice is very different from Shh null mice, indicating that fused is not critical for Hh signaling during early embryonic development in mice.

In addition to the Drosophila homologues, mammalian cells have several novel cytoplasmic regulators of Hh signaling, including Rab23 and tectonic. Rab23 and tectonic are all negative regulators downstream of SMO. We have shown that Rab23 is involved in Gli–SuFu interaction (see Figure 1). Unlike many Rab proteins, we found that Rab23 is localized both in the nucleus and in cytoplasm, suggesting that Rab23 may have other unrevealed functions apart from membrane trafficking.

The ultimate effect of Hh signaling is activation of downstream Gli transcription factors, which regulate target genes by directly binding a consensus binding site in human cancer. The activity of Gli transcription factors can be regulated at several levels. First, nuclear–cytoplasmic shuffling of Gli molecules is tightly regulated. Protein kinase A can retain Gli1 protein in the cytoplasm via a protein kinase A site in the nuclear localization signal domain, whereas activated Ras signaling induces Gli nuclear localization. Second, ubiquitination, acetylation, and protein degradation of Gli molecules are regulated by several distinct mechanisms, including β-TRCP, cul3/BTB-, and numb/itch-mediated Gli ubiquitination, sumoylation, and acetylation. In addition, Gli3 (Gli2 to a lesser extent) can be processed into transcriptional repressors, which may be mediated by the β-TRCP E3 ligase. SuFu not only prevents nuclear translocation of Gli molecules but also inhibits Gli1-mediated transcriptional activity. Other mechanisms to modify Gli functions include interaction with a negative regulator sucorese nonfermenting 5 (SNF5) and a positive regulator protein kinase C isoform tα.

Several feedback regulatory loops exist in this pathway to maintain a certain level of Hh signaling in a given cell. PTC, HIP, GAS1, neureilins, and Gli1 are components, as well as the target genes of this pathway. PTC and HIP provide negative feedback regulation, whereas Gli1 and Nrp1/2 form positive regulatory loops. On the other hand, GAS1 is downregulated by the Hh pathway but is a positive regulator for Hh signaling. Alterations of these loops would lead to abnormal signaling of this pathway, such as inactivation of PTCH1 in BCCs.

### Activation of the Hh pathway in human cancer

The initial link between Hh signaling and human cancers was made from the discovery that mutations of human PTCH1 are associated with a rare and hereditary form of BCC, basal cell nevus syndrome (BCNS) (also Gorlin syndrome). Gorlin syndrome is a rare autosomal genetic disease with two
distinct sets of phenotypes: an increased risk of developing cancers such as BCCs, medulloblastomas, rhabdomyosarcomas, and meningiomas, as well as developmental defects such as bifid ribs and ectopic calcification.\textsuperscript{104}

Almost all BCCs and about 30% of medulloblastomas have activated Hh signaling via gene mutations in PTCH1, SMO, or other Hh pathway molecules.\textsuperscript{105–109} In addition, cancers associated with Gorlin syndrome, including rhabdomyosarcoma\textsuperscript{10,111} and meningiomas,\textsuperscript{112–114} are reported to have gene mutations in the Hh signaling pathway or elevated Hh target gene expression. Activated Hh signaling has been detected in a variety of human cancer types, either in the tumor or in the stroma.\textsuperscript{100,115–117}

Genetically engineered mice with Ptc{h}I and Smo genes have generated more convincing evidence for the critical role of Hh signaling in cancer. In addition to BCCs and medulloblastomas, rhabdomyosarcomas develop in mice with expression of oncogenic Smo{M2} or knockout of Ptc{h}I.\textsuperscript{118–121} One surprising finding from tissue-specific Ptc{h}I knockout is the development of gastrointestinal stromal-like tumors (GIST),\textsuperscript{122} suggestive of a role of Hh signaling in GIST. Even in the situation of a small cell lung cancer (SCLC) mouse model, expression of oncogenic Smo{M2} increases the tumor number, whereas Smo knockout reduces the tumor number.\textsuperscript{123} Recent study of Barrett’s esophagus indicates that sonic Hh expression in the epithelium of the esophagus can lead to stromal expression of Hh signaling target genes, which is similar to the human situation.\textsuperscript{124,125} In contrast, tissue-specific expression of oncogenic Smo molecule Smo{M2} has no effects on K-Ras-induced pancreatic cancer\textsuperscript{126} or on prostate cancer.\textsuperscript{127} The negative data, however, do not rule out the promoting effects of Hh signaling for tumor metastasis, a major factor for cancer mortality. Currently, there are only a limited number of mouse models for cancer metastasis. Even for the available mouse models for cancer metastasis, several variable factors make cancer metastasis models less robust, and these factors include mouse genetic backgrounds, low incidence, and long duration to observe metastasis in mice.

**Hh signaling in tumor initiation, promotion, and metastases**

Hh signaling plays different roles in different types of cancer.\textsuperscript{100} Based on the published data, we attempt to divide the functions of Hh signaling during cancer development into three types: the tumor driver, the tumor promoter, or the regulator for residual cancer cells after therapy. For example, activated Hh signaling can drive development of BCCs, medulloblastomas, rhabdomyosarcoma, GIST, and Barrett’s esophagus,\textsuperscript{118,119,122,124,128,129} and Hh signaling in these lesions serves as the tumor driver, at least in the mouse models. For SCLC, Hh signaling can promote cancer development but is not sufficient to drive tumor formation, and thus serves as a tumor promoter.\textsuperscript{123} In pancreatic cancer, inhibition of Hh signaling does not affect tumor formation but can promote tumor metastasis.\textsuperscript{130–137} For other cancer types, Hh signaling may regulate the number of cancer stem cells or the tumor microenvironment, such as leukemia and liver cancer.\textsuperscript{138,139} As more in vivo data are available, we predict more revelation of the tumor promoting role of Hh signaling. Tumor recurrence after therapy is a major issue in clinical care of cancer patients, such as chemotherapy or radiotherapy resistance, and will be discussed in “Hh signaling, cancer stem cell, and residual cancer cells.” For some cancer types, Hh signaling may not have any roles to play.

Activation of Hh signaling does not work in isolation but rather crosstalks with other signaling pathways during cancer development and metastasis. Earlier studies indicated that Ptc{h}I\textsuperscript{c–c} mice with P53 knock out all developed medulloblastomas, whereas <30% of Ptc{h}I\textsuperscript{c–c} mice (with wild-type P53) had this type of tumor.\textsuperscript{110} We have shown that skin-specific knockout of Stat3 or its upstream activator Il11ra significantly reduced Hh signaling-mediated BCC formation.\textsuperscript{141} Increasing data have indicated close collaboration between Hh signaling and growth factor signaling pathways. Our earlier work indicated that platelet-derived growth factor alpha (PDGFR\textalpha) is regulated by Hh signaling and is responsible for cell proliferation in BCCs.\textsuperscript{142} Now more links are reported between Hh and other pathways, including epidermal growth factor, insulin growth factor, transforming growth factor beta (TGF\beta), mTOR/S6K1, RACK1, notch, and protein kinase C.\textsuperscript{100,143–151} Although some of these molecules are involved in regulation of tumor microenvironment, such as TGF\beta, others are known to regulate cancer stem cells, such as PDGFR\textalpha and notch. We will have more discussion on cancer stem cells in “Hh signaling, cancer stem cell, and residual cancer cells.”

Increasing evidence indicates that Hh signaling plays an important role during tumor metastasis in several types of cancer, such as pancreatic and breast cancers.\textsuperscript{135,132} Studies from many groups indicate activation of Hh signaling in the stromal as well as tumor compartments in metastatic pancreatic cancer.\textsuperscript{130,133–137,153} In fact, Hh signaling inhibitors are effective in suppressing tumor metastases of pancreatic cancer.\textsuperscript{135} Hh signaling also regulates bone homeostasis as well as bone metastasis in breast cancer independent of
the Hh ligands. During tumor metastasis, Hh signaling activation is observed both in the tumor compartment and in the stroma. The molecules mediating Hh’s metastatic functions remain largely untested, but there are reports to indicate the following molecules: snail, TGFβ, Wnt, HGF, and muc5 AC. Further studies will be needed to understand the molecular basis by which Hh signaling mediates cancer metastases.

Hh signaling inhibitors: preclinical and clinical studies

More than 200 compounds have been disclosed to have inhibitory effects on Hh signaling. Of these, eight have been used for clinical trials (see Table 1 for the list). There are three major targeting sites for Hh signaling inhibitors identified so far: Hh molecules (Shh neutralizing antibodies, small molecule Robotnikinin), SMO protein (cyclopamine and its derivatives IPI-926 and CycT), and synthetic compounds GDC-0449, XL-139/BMS833923, LDE-225, PF04449913, and LY2940680), and Gli inhibitors (HPI-1, HPI-2, GANT-56, and GANT-61). The major advances include successful clinical trials using GDC-0449 and US Food and Drug Administration approval of GDC-0449 for treatment of locally advanced and metastatic BCCs. However, combination of Hh signaling inhibitors with gemcitabine or Hh signaling inhibitors alone did not show any improvements in the outcomes of pancreatic cancer patients. We summarize these data below.

Table 1 shows the list of Hh signaling inhibitors in clinical trials, with all eight small molecules targeting SMO. Clinical trials with GDC-0449 in BCCs are the most successful. The successful Phase II clinical trials were preceded with a remarkable Phase I clinical trial in patients with metastatic BCCs. This drug is well tolerated by patients. Two independent groups used GDC-0449 to treat BCNS patients and sporadic BCCs, respectively, via oral administration. Although the overall outcomes were very encouraging, the responses of two groups of patients were quite different. Although BCNS patients had virtually a 100% response rate, sporadic BCCs had only a 33% response rate. Previous studies in mouse models indicate that tumors acquire somatic mutations in Smo or other signaling pathways following GDC-0449 administration, which may explain why not all sporadic BCCs responded well. A more rational way to treat sporadic BCCs is topical application. Two groups (one from Novartis AG and one from Hoffmann-La Roche Ltd/Genentech) indeed tested that possibility with BCNS patients and obtained impressive responses. Mechanisms to Smo antagonist resistance include mutations in the target SMO gene or alterations in the PI3K pathway. Several ways have been explored to mitigate drug resistance to Smo antagonists, such as iraconazole and arsenic trioxide, polymeric nanoparticle-encapsulated Hh signaling inhibitors, or vitamin D3. Hopefully, some of these combined treatments will provide benefits to BCC patients.

Studies in animal models demonstrated significant inhibition of Hh signaling inhibitors on medulloblastoma development. For example, oral administration of IPI-926 or PF-5274857 can reduce tumor development, leading to a longer lifespan in mouse medulloblastoma models. However, an early clinical trial on a medulloblastoma patient using GDC-0449 yielded only a transient therapeutic effect, due to an SMO mutation occurring soon after treatment. The outcome data of current medulloblastoma clinical trials are not available, but there is still a high expectation.

There is evidence to support that rhabdomyosarcoma is very responsive to Hh signaling inhibitors. First, gene expression analyses revealed elevated Hh target gene expression in embryonic rhabdomyosarcomas. Second, preliminary studies used forskolin or SMO inhibitor to shrink tumors in mouse models. In addition, evidence for Hh signaling in meningiomas and SCLC is quite clear, and

Table 1 A list of hedgehog signaling inhibitors in clinical trials (from http://clinicaltrials.gov)*

| Molecule      | Other names        | Phase | Tumor types                  | FDA approval | Company                        |
|---------------|--------------------|-------|------------------------------|-------------|--------------------------------|
| GDC-0449      | Vismodegib/erivedge| I/II/III | BCCs and solid tumors | BCCs | Hoffman-La Roche Ltd          |
| IPI-926       |                    | II    | Solid tumors                 |             | Infinity Pharmaceuticals, Inc. |
| LDE225        |                    | II    | Leukemia and solid tumors    |             | Novartis AG                    |
| LEQ506        |                    | I     | Solid tumors                 |             | Novartis AG                    |
| PF-04449913   |                    | I/II  | Leukemia and solid tumors    |             | Pfizer, Inc.                  |
| TAK-441       |                    | I     | Solid tumors                 |             | Millennium Pharmaceuticals, Inc.|
| BMS833923     | XL-139             | I/II  | SCLC and solid tumors        |             | Bristol-Myers Squibb           |
| LY2940680     |                    | I/II  | SCLC/advanced cancer         |             | Eli Lilly and Company          |

Notes: All small molecules target smoothened molecule. GDC-0449 has been approved by the FDA to treat locally advanced and metastatic BCCs. There are no ongoing clinical trials for LEQ506, TAK-441, and BMS833923.

Abbreviations: BCC, basal cell carcinoma; FDA, US Food and Drug Administration; SCLC, small cell lung cancer.
Hh signaling inhibitors should be effective in these tumor types as well.

**Hh signaling, cancer stem cell, and residual cancer cells**

Increasing evidence indicates that Hh signaling is critical for cancer stem cell maintenance and function. For example, leukemia stem cell maintenance and expansion are dependent on Hh signaling. The effect of Hh signaling on a normal hematopoietic stem cell population, however, is still quite controversial, with some showing effects but others with no effects. Based on cancer stem cell theory, it is anticipated that Hh signaling activation exerts resistance to cancer chemotherapy and radiotherapy. Several studies have indeed shown that Hh signaling activation is associated with chemotherapy or radiotherapy resistance. Hh signaling inhibitor IPI-926 enhances delivery of the chemotherapeutical drug gemcitabine in a mouse model of pancreatic cancer. Relevance to the cancer stem cell theory is the link between Hh signaling activation and cancer relapse from drug resistance.

Based on the published data, we propose that Hh signaling may help maintain the stemness of cancer stem cells, which are generally insensitive to chemotherapy and radiotherapy. There is evidence to indicate that Hh signaling regulates expression of cancer stem cell-related markers, such as aldehyde dehydrogenase, Bmi1, snail, Wnt2, PDGFRA, jagged-1, CD44, and c-MET. The level of Hh expression is often higher in the cancer stem cell population in several cancer types. Thus, we have reasons to believe that inhibition of Hh signaling may be effective in reducing the number of cancer stem cells, which may play an important role in chemotherapy and radiotherapy resistance.

Chemotherapy and radiotherapy play an important role in the clinical care of cancer patients, but resistance to these treatments remains a major obstacle in cancer patient care. Recent studies revealed a few examples for the role of Hh signaling in chemotherapy and radiotherapy resistance. Resistance to docetaxel is a major clinical challenge for prostate cancer patients. A recent study revealed an important role of Hh signaling on docetaxel resistance in prostate cancer. Combination of notch and Hh signaling inhibitors was able to reverse docetaxel resistance both in cultured cells and in xenografts. Activation of Hh signaling via PI3 K is also reported in tamoxifen-resistant breast cancer, and a combination of Hh signaling inhibitor GDC-0449 with tamoxifen significantly reduced cell colony formation and tumor development in xenografts. In addition, activated Hh signaling is shown to be responsible for drug resistance in ovarian cancer, cervical cancer, and myeloid leukemic cells. A recent study also suggests that Hh signaling may be associated with antiepidermal growth factor receptor therapy (targeted therapy) resistance observed in head and neck cancer. The exact mechanisms by which Hh signaling activation confers drug resistance are not entirely clear, but it is reported that Hh signaling can regulate expression of several drug resistance-related genes such as ABCG2 and MDR. The cancer stem cell theory can also explain some of the mechanisms.

Overcoming recurrence to radiotherapy is also very challenging, but recent studies suggest that inhibiting Hh signaling may help mitigate radiotherapy resistance in pancreatic and head/neck cancer. For pancreatic cancer, we found that a combination of Hh signaling inhibitor BMS833932 (see Table 1 for details) and radiation could significantly reduce the number of lymph node metastasis. Similarly, high expression of Gli1 is reported to be associated with lymph node metastases and tumor progression after radiotherapy in squamous cell carcinomas of the head/neck.

**Summary and future perspectives**

In summary, the link of Hh signaling activation to a variety of human cancer implies the relevance of studying Hh signaling to human health. Rapid advancement in the discovery of novel Hh signaling inhibitors has provided many opportunities for developing novel cancer therapeutic strategies. It is not surprising to learn that several major challenges still exist to prevent the use of Hh signaling inhibitors in clinics. These challenges include a lack of basic understanding of the molecular mechanisms by which Hh signaling mediates carcinogenesis; no clear criteria to identify the right tumors for therapeutic application; only a few reliable, physiologically relevant, and reproducible mouse models for cancer metastases to test and optimize drug dosages in order to minimize side effects; and a lack of clear strategies to mitigate drug resistance. Over the last 3 years, research in this area has greatly improved, as indicated in this review. It is anticipated that additional novel therapeutic strategies will be developed for cancer clinical trials using Hh signaling inhibitors in the next few years.

**Acknowledgment**

Current research in the authors’ laboratory is supported by grants from the National Cancer Institute (CA94160, CA155086), Riley Children’s Foundation, and Wells Center for Pediatric Research. Due to space limit, we could not...
include many important findings in this review but want to take this opportunity to thank all the investigators in this field for their work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. *Nature*. 1980;287(5785):795–801.

2. Krauss S, Concordet JP, Ingham PW. A functionally conserved homolog of the Drosophila segment polarity gene hh is expressed in tissues with polarizing activity in zebrafish embryos. *Cell*. 1993;75(7):1431–1444.

3. Ec蚀lard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. *Cell*. 1993;75(7):1417–1430.

4. Riddle RD, Johnson RL, Laufer E, Tabin C. Sonic hedgehog mediates the polarizing activity of the ZPA. *Cell*. 1993;75(7):1401–1416.

5. Chang DT, Lopez A, von Kessler DP, et al. Products, genetic linkage and limb patterning activity of a murine hedgehog gene. *Development*. 1994;120(11):3339–3353.

6. Roelink H, Augsburger A, Heemskerk J, etc. Floor plate and motor neuron induction by hh-l, a vertebrate homolog of hedgehog expressed by the notochord. *Cell*. 1994;76(4):761–775.

7. Epstein EH. Basal cell carcinomas: attack of the hedgehog. *Nat Rev Cancer*. 2008;8(10):743–754.

8. Xie J. Hedgehog signaling in prostate cancer. *Future Oncol*. 2005;1(3):331–338.

9. Xie J. Hedgehog signaling pathway: development of antagonists for cancer therapy. *Curr Oncol Rep*. 2008;10(2):107–113.

10. Xie J. Molecular biology of basal and squamous cell carcinomas. *Adv Exp Med Biol*. 2008;624:241–251.

11. Jiang J, Hui CC. Hedgehog signaling in development and cancer. *Dev Cell*. 2008;15(6):801–812.

12. Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. *Nat Rev Genet*. 2001;2(11):841–850.

13. Sasaki H, Hui C, Nakamure M, Kondoh H. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. *Development*. 1997;124(7):1313–1322.

14. Kinzler KW, Vogelstein B. The Gli gene encodes a nuclear protein which binds specific sequences in the human genome. *Mol Cell Biol*. 1990;10(2):634–642.

15. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. *Curr Top Dev Biol*. 2003;53:1–114.

16. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev*. 2001;15(23):3059–3087.

17. Taipale J, Beachy PA. The hedgehog and Wnt signalling pathways in cancer. *Nature*. 2001;411(6835):349–354.

18. Lee JJ, Ekker SC, von Kessler DP, Porter JA, Sun BI, Beachy PA. Autoproteolysis in hedgehog protein biogenesis. *Science*. 1994;266(5190):1528–1537.

19. Porter JA, Young KE, Beachy PA. Cholesterol modification of hedgehog signaling proteins in animal development. *Science*. 1996;274(5285):255–259.

20. Porter JA, von Kessler DP, Ekker SC, etc. The product of hedgehog autoproteolytic cleavage active in local and long-range signalling. *Nature*. 1995;374(6520):363–366.

21. Bugliano JA, Resh MD. Hhat is a palmitoylacyltransferase with specificity for N-palmitoylation of sonic hedgehog. *J Biol Chem*. 2008;283(12):22076–22083.

22. Kawakami T, Kawcak T, Li YJ, Zhang W, Hu Y, Chuang PT. Mouse dispatched mutants fail to distribute hedgehog proteins and are defective in hedgehog signaling. *Development*. 2002;129(24):5753–5765.

23. Ma Y, Erkner A, Gong R, et al. Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched. *Cell*. 2002;111(1):63–75.

24. Caspary T, Garcia-Garcia MJ, Huangfu D, et al. Mouse dispatched homolog1 is required for long-range, but not juxtacrine, Hh signaling. *Curr Biol*. 2002;12(18):1628–1632.

25. Dierker T, Dreier R, Petersen A, Bordyck C, Grohe K. Heparan sulfate-modulated, metalloprotease-mediated sonic hedgehog release from producing cells. *J Biol Chem*. 2009;284(12):8013–8022.

26. Beckett K, Franch-Marro X, Vincent JP. Glypican-mediated endocytosis of hedgehog has opposite effects in flies and mice. *Trends Cell Biol*. 2008;18(8):360–363.

27. Lum L, Yao S, Mozer B, et al. Identification of hedgehog pathway components by RNAi in Drosophila cultured cells. *Science*. 2003;299(5615):2039–2045.

28. Baena-Lopez LA, Rodriguez I, Baonza A. The tumor suppressor genes dachous and fat modulate different signalling pathways by regulating daily and daily-like. *Proc Natl Acad Sci U S A*. 2008;105(28):9645–9650.

29. Toyoda H, Kinoshita-Toyoda A, Fox B, Selleck SB. Structural analysis of glycosaminoglycans in animals bearing mutations in sugarless, sulfateless, and tool-velu. Drosophila homologues of vertebrate genes encoding glycosaminoglycan biosynthetic enzymes. *J Biol Chem*. 2000;275(29):21856–21861.

30. Bellaiche Y, The I, Perrimon N. Tool-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion. *Nature*. 1998;394(6688):85–88.

31. Koziel L, Kunath M, Kelly OG, Vortkamp A. Ext1-dependent heparan sulfate regulates the range of hh signaling during endochondral ossification. *Dev Cell*. 2004;6(6):801–813.

32. Stone DM, Hynes M, Armanini M, et al. The tumour-suppressor gene patched encodes a candidate receptor for sonic hedgehog. *Nature*. 1996;384(6605):129–134.

33. Taipale J, Cooper MK, Maiti T, Beachy PA. Patched acts catalytically to suppress the activity of smoothed. *Nature*. 2002;418(6900):892–897.

34. Chuang PT, McMahon AP. Vertebrate hedgehog signalling modulated by induction of a hedgehog-binding protein. *Nature*. 1999;397(6720):617–621.

35. Martinelli DC, Fan CM. Gas1 extends the range of hedgehog action by binding to hedgehog. *Nat Rev Genet*. 2000;1:572–588.

36. Peppin DB, Moors J, Smith K, et al. The hedgehog signalling pathway and feedback network in mice. *Cell*. 2002;107(5):647–656.

37. Allen BL, Tenzen T, McMahon AP. The hedgehog-binding proteins Gas1 and Cdo cooperate to positively regulate Shh signaling during mouse development. *Genes Dev*. 2007;21(10):1231–1243.

38. Seppala M, Depew MJ, Martinelli DC, Fan CM, Sharpe PT, Cobourne MT. Gas1 is a modifier for holoprosencephaly and genetically interacts with sonic hedgehog. *J Clin Invest*. 2007;117(6):1575–1584.

39. Allen BL, Tenzen T, McMahon AP. The hedgehog-binding proteins Gas1 and Cdo cooperate to positively regulate Shh signaling during mouse development. *Genes Dev*. 2007;21(10):1244–1257.

40. Okada A, Charron F, Morin S, et al. Boc is a receptor for sonic hedgehog in the guidance of commissural axons. *Nature*. 2006;444(7117):369–373.

41. Tenzen T, Allen BL, Cole F, Kang JS, Krauss RS, McMahon AP. The cell surface membrane proteins Cdo and Cbo are components and targets of the hedgehog signaling pathway and feedback network in mice. *Dev Cell*. 2006;10(5):647–656.

42. Zhang W, Kang JS, Cole F, Yi MJ, Krauss RS. Cdo functions at multiple points in the sonic hedgehog pathway, and Cdo-deficient mice accurately model human holoprosencephaly. *Dev Cell*. 2006;10(5):657–665.
64. Witt RM, Hecht ML, Pazzyra-Murphy MF, et al. Heparan sulfate proteoglycans containing a glypicain 5 core and 2-O-sulfo-iduronic acid function as sonic hedgehog co-receptors to promote proliferation. J Biol Chem. 2013;288(36):26275–26288.

65. Snuderl M, Honeyager SM, Malicik J, Blair SS. The role of glypicans in Wnt inhibitory factor-1 activity and the structural basis of Wif’s effects on Wnt and hedgehog signaling. PLoS Genet. 2012;8(2):e1002503.

66. Cao Y, Wang L, Nandy D, et al. Neurupulin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res. 2008;68(21):8667–8672.

67. Parra LM, Zou Y. Sonic hedgehog induces response of commissural axons to Semaphorin repulsion during midline crossing. Nat Neurosci. 2010;13(1):29–35.

68. Cheung HO, Zhang X, Ribeiro A, et al. The kinesin protein Kif7 is a critical regulator of Gli transcription factors in mammalian hedgehog signaling. Sci Signal. 2009;2(76):ra29.

69. Endoh-Yamagami S, Evangelista M, Wilson D, et al. The mammalian CoX2 homolog Kif7 plays an essential role in modulating Hh signal transduction during development. Curr Biol. 2009;19(15):1320–1326.

70. Law KK, Makino S, Mo R, Zhang X, Puvindran V, Hui CC. Antagonistic and cooperative actions of Kif7 and Sufu define graded intracellular Gli activities in hedgehog signaling. PLoS One. 2012;7(11):e50193.

71. Li ZJ, Nieuwenhuis E, Nien W, et al. Kif7 regulates Gli2 through Sufu-dependent and -independent functions during skin development and tumorigenesis. Development. 2012;139(24):4152–4161.

72. Hsu SH, Zhang X, Yu C, et al. Kif7 promotes hedgehog signaling in growth plate chondrocytes by restricting the inhibitory function of Sufu. Development. 2011;138(17):3791–3801.

73. Wilson CW, Nguyen CT, Chen MH, et al. Fusion has evolved divergent roles in vertebrate hedgehog signalling and motile ciliogenesis. Nature. 2009;459(7243):98–102.

74. Merchant M, Evangelista M, Luoh SM, et al. Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalus. Mol Cell Biol. 2005;25(16):7054–7068.

75. Chen MH, Gao N, Kawakami T, Chuang PT. Mice deficient in the fused homolog do not exhibit phenotypes indicative of perturbed hedgehog signaling during embryonic development. Mol Cell Biol. 2005;25(16):7042–7053.

76. Eggenschwiler JT, Espinoza E, Anderson KV. Rab23 is an essential negative regulator of the mouse sonic hedgehog signalling pathway. Nature. 2001;412(6843):194–198.

77. Reiter JF, Skarnes WC. Tectonic, a novel regulator of the hedgehog pathway required for both activation and inhibition. Genes Dev. 2006;20(1):22–27.

78. Li C, Chi S, Xie J. Hedgehog signaling in skin cancers. Cell Signal. 2011;23(8):1235–1243.

79. Huang S, Yang L, An Y, et al. Expression of hedgehog signaling molecules in lung cancer. Acta Histochem. 2011;113(5):564–569.

80. Kinzler KW, Ruppert JM, Bigner SH, Vogelstein B. The Gli gene is a member of the Kruppel family of zinc finger proteins. Nature. 1988;332(6162):371–374.

81. Ruppert JM, Kinzler KW, Wong AJ, et al. The Gli-Kruppel family of human genes. Mol Cell Biol. 1988;8(8):3104–3113.

82. Barnfield PC, Zhang X, Thanabalasingham V, Yoshida M, Hui CC. Negative regulation of Gli1 and Gli2 activator function by suppressor of fused through multiple mechanisms. Differentiation. 2005;73(8):397–405.

83. Sheng T, Chi S, Zhang X, Xie J. Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal. J Biol Chem. 2006;281(1):9–12.

84. Kogerman P, Grimm T, Kogerman L, et al. Mammalian suppressor-of-fused homolog do not exhibit phenotypes indicative of perturbed hedgehog signaling. Nat Cell Biol. 1999;1(5):312–319.

85. Stecca B, Mas C, Clement V, et al. Melanomas require hedgehog-Gli signaling regulated by interactions between Gli1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A. 2007;104(14):5895–5900.

86. Pan Y, Bai CB, Joyner AL, Wang B. Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. Mol Cell Biol. 2006;26(9):3365–3377.

87. Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, Oro AE. Dual degradation signals control Gli protein stability and tumor formation. Genes Dev. 2006;20(3):276–281.
88. Wang B, Li Y. Evidence for the direct involvement of βTRCP in Gli3 protein processing. Proc Natl Acad Sci U S A. 2006;103(1):33–38.
89. Di Marzotulli L, Ferretti E, Greco A, et al. Numb is a suppressor of hedgehog signalling and targets Gli3 for Ick-dependent ubiquitination. Nat Cell Biol. 2006;8(12):1415–1423.
90. Jiang J. Regulation of Hh/Gli signaling by dual ubiquitin pathways. Cell Cycle. 2006;5(21):2457–2463.
91. Conietti G, Di Marzotulli L, Greco A, et al. Histone deacetylase and Cullin-3-RN (KCTD11) ubiquitin ligase interplay regulates hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010;12(2):132–142.
92. Coni S, Antonucci L, D’Amico D, et al. Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy. PLoS One. 2013;8(6):e65718.
93. Han L, Pan Y, Wang B. Small ubiquitin-like modifier (SUMO) modification inhibits Gli2 protein transcriptional activity in vitro and in vivo. J Biol Chem. 2012;287(24):20483–20489.
94. Zhang Q, Shi Q, Chen Y, et al. Multiple Ser/Thr-rich degrons mediate the degradation of Ci/Gli with the Cul3-HIB/SPOP E3 ubiquitin ligase. Proc Natl Acad Sci U S A. 2009;106(50):21191–21196.
95. Cheng SY, Bishop JM. Suppressor of fused represses Gli-mediated transcription by recruiting the SAP18-mSin3 corepressor complex. Proc Natl Acad Sci U S A. 2002;99(8):5442–5447.
96. Wang C, Pan Y, Wang B. Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors. Development. 2010;137(12):2001–2009.
97. Li ZJ, Mack SC, Mak TH, Angers S, Taylor MD, Hui CC. Evasion of p53 and G/M checkpoints are characteristic of Hh-driven basal cell carcinoma. Oncogene. Epub June 10, 2013.
98. Jagani Z, Mora-Blanco EL, Sansam CG, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the hedgehog-Gli pathway. Nat Med. 2010;16(12):1429–1433.
99. Atwood SX, Li M, Lee A, Tang JY, Oro AE. Gli activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature. 2013;494(7438):484–488.
100. Yang L, Xie G, Fan Q, Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene. 2010;29(4):469–481.
101. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841–851.
102. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal nevus syndrome. Science. 1996;272(5268):1668–1671.
103. Epstein E Jr. Genetic determinants of basal cell carcinoma risk. Med Pediatr Oncol. 2001;36(5):555–558.
104. Gorlin RJ. Neviod basal-cell carcinoma syndrome. Medicine. 1987;66(2):98–113.
105. Xie J, Murone M, Luoh SM, et al. Activating smoothed mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–92.
106. Lam CW, Xie J, To KF, et al. A frequent activated smoothed mutation in sporadic basal cell carcinomas. Oncogene. 1999;18(3):833–836.
107. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152(1):43–51.
108. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998;58(9):1798–1803.
109. Couve-Privat S, Boudajar B, Avril MF, Sarasin A, Daya-Grosjean L. Significantly high levels of ultraviolet-specific mutations in the smoothed gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res. 2002;62(24):7186–7189.
110. Tostar U, Malm CJ, Meis-Kendall JM, Kindblom LG, Toftgard R, Unden AB. Deregression of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhadomyoma and rhabdomyosarcoma development. J Pathol. 2006;208(1):17–25.
111. Pressy JG, Anderson JR, Crossman DK, Lynch JC, Barr FG. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2011;57(6):930–938.
112. Clark VE, Ersin-Ornay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6213):1077–1080.
113. Avakko M, Li SP, Saarinen S, et al. Loss of SUFU function in familial multiple meningioma. Am J Hum Genet. 2012;91(3):520–526.
114. Kijima C, Miyashita T, Suzuki M, Oka H, Fujii K. Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation. Fam Cancer. 2012;11(4):565–570.
115. Fei DL, Sanchez-Mejias A, Wang Z, et al. Hedgehog signaling regulates bladder cancer growth and tumorigenicity. Cancer Res. 2012;72(17):4449–4458.
116. Rodriguez-Blanco J, Schilling NS, Tokhunts R, et al. The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene. 2013;32(18):2335–2345.
117. Shin K, Lee J, Guo N, et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472(7341):110–114.
118. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med. 1998;4(5):619–622.
119. Hatley ME, Tang W, Garcia MR, et al. A mouse model of rhabdomyosarcoma originating from the adipooyte lineage. Cancer Cell. 2012;22(4):536–546.
120. Ignatius MS, Chen E, Elpek NM, et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell. 2012;21(5):680–693.
121. Nitzki F, Zibat A, Frommhold A, et al. Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous patched1-mutant mice. Oncogene. 2011;30(43):4428–4436.
122. Pelczar P, Zibat A, van Dop WA, et al. Inactivation of patched1 in mice leads to development of gastrointestinal stromal-like tumors that express PDGFRe but not kit. Gastroenterology. 2013;144(1):134–144.
123. Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for hedgehog signaling in small cell lung cancer. Nat Med. 2011;17(11):1504–1508.
124. Wang DH, Clemons NJ, Miyashita T, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett’s metaplasia. Gastroenterology. 2010;138(5):1810–1822.
125. Yang L, Wang LS, Chen XL, et al. Hedgehog signaling activation in the development of squamous cell carcinoma and adenoacarcoma of esophagus. Int J Biochem Mol Biol. 2012;3(1):46–57.
126. Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A. 2009;106(11):4254–4259.
127. Mao J, Ligon KL, Rahlin EY, et al. A novel somatic mouse model to survey tumorigenic potential applied to the hedgehog pathway. Cancer Res. 2006;66(20):10171–10178.
128. Axterbaum M, Epstein J, Oro A, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med. 1999;5(11):1285–1291.
129. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural crest cell fate and medulloblastoma in mouse patched mutants. Science. 1997;277(5329):1109–1113.
130. Feldmann G, Dhara S, Hendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67(5):2187–2196.
131. Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasmia in pancreatic cancer. Clin Cancer Res. 2008;14(19):5995–6004.
132. Chang Q, Foltz WD, Chaudary N, Hill RP, Hedley DW. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. *Int J Cancer*. 2013;131(1):225–234.

133. Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. *Int J Cancer*. 2012;131(1):30–40.

134. Feldmann G, Fendrich V, McGovern K, et al. An orally bioavailable small-molecule inhibitor of hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. *Mol Cancer Ther*. 2008;7(9):2725–2735.

135. Gu D, Liu H, Su GH, et al. Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. *Mol Cancer Ther*. 2013;12(6):1038–1048.

136. Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. *Oncogene*. 2009;28(40):3513–3525.

137. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science*. 2009;324(5933):1457–1461.

138. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukemia. *Nature*. 2009;458(7239):776–779.

139. Boyd AL, Salci KR, Shapovalova Z, McIntyre BA, Bhatia M. IGF2-mediated Akt activation.

140. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(-/-) mice. *Cancer Cell*. 2004;6(3):229–240.

141. Gu D, Fan Q, Zhang X, Xie J. A role for transcription factor STAT3 signaling in oncogene smoothed-driven carcinogenesis. *J Biol Chem*. 2012;287(45):38356–38366.

142. Xie J, Asztterbaum M, Zhang X, et al. A role of PDGFRalpha in basal cell carcinoma proliferation. *Proc Natl Acad Sci U S A*. 2001;98(16):9255–9259.

143. Johnson RW, Nguyen MP, Padalecki SS, et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. *Cancer Res*. 2011;71(3):822–831.

144. Keysar SB, Le PN, Anderson RT, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. *Cancer Res*. 2013;73(11):3381–3392.

145. Eberl M, Klingler S, Mangelberger D, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. *EMBO Mol Med*. 2012;4(3):218–233.

146. Fan Q, He M, Sheng T, et al. Requirement of TGFbeta signaling for SMO-mediated carcinogenesis. *J Biol Chem*. 2010;285(47):36570–36576.

147. Wang Y, Ding Q, Yen CJ, et al. The crosstalk of mTOR/S6K1 and hedgehog pathways. *Cancer Cell*. 2012;21(3):374–387.

148. Shi S, Deng YZ, Zhao JS, et al. RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway. *J Biol Chem*. 2012;287(11):7845–7858.

149. Hsieh A, Ellsworth R, Hsieh D. Hedgehog/Gli1 regulates IGF dependent malignant behaviors in glioma stem cells. *J Cell Physiol*. 2011;226(4):1118–1127.

150. Mainwarin LA, Kenney AM. Divergent functions for Eif4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum. *Oncogene*. 2011;30(15):1784–1797.

151. Fernandez LA, Squatrito M, Northcott P, et al. Oncogenic YAP promotes radioreosistance and genomic instability in medulloblastoma through IGFB2-mediated Akt activation. *Oncogene*. 2012;31(15):1923–1937.

152. Heller E, Hurchla MA, Xiang J, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. *Cancer Res*. 2012;72(4):897–907.

153. Abbuzzese JL, National Institutes of Health (US). Are there new targets for pancreatic cancer therapeutics? 2007. Available from: http://videocast.nih.gov/launch.asp?13834. Accessed September 10, 2013.

154. Inaguma S, Kasai K, Ikeda H. Gli1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin. *Oncogene*. 2011;30(6):714–723.

155. Joost S, Almada LL, Rohnalter V, et al. Gli1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. *Cancer Res*. 2012;72(12):88–99.

156. Li X, Deng W, Lobo-Ruppert SM, Ruppert JM. Gli acts through snail and E-cadherin to promote nuclear signaling by beta-catenin. *Oncogene*. 2007;26(31):4489–4498.

157. Javelaud D, Pierrat MJ, Mauveil A. Crosstalk between TGF-beta and hedgehog signaling in cancer. *FEBS Lett*. 2012;586(14):2016–2025.

158. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med*. September 17, 2009;361(12):1164–1172.

159. Graham RA, Lum BL, Cheeth S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. *Clin Cancer Res*. 2011;17(8):2512–2520.

160. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. *Clin Cancer Res*. 2011;17(8):2502–2511.

161. Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. *Clin Cancer Res*. 2011;17(17):5774–5782.

162. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. *Cancer Res*. 2011;71(15):5057–5061.

163. Tang T, Tang JY, Li D, et al. Targeting superficial or nodular basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. *Clin Cancer Res*. 2011;17(10):3378–3387.

164. Skvava H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. *J Invest Dermatol*. 2011;131(8):1735–1744.

165. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. *Sci Transl Med*. 2010;2(51):51ra70.

166. Dijkstra GF, Aileeke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. *Cancer Res*. 2011;71(2):435–444.

167. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. *Cancer Cell*. 2012;23(1):23–34.

168. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used anti-fungal that inhibits hedgehog pathway activity and cancer growth. *Cancer Cell*. 2010;17(4):388–399.

169. Tang JY, Xiao TZ, Oda Y, et al. Vitamin D3 inhibits hedgehog signaling and proliferation in murine basal cell carcinomas. *Cancer Prev Res (Phila)*. 2011;4(5):744–751.

170. Chenha V, Hu C, Pramanik D, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of hedgehog signaling (NanohHI) bypasses secondary mutational resistance to smoothened antagonists. *Mol Cancer Ther*. 2012;11(1):165–173.

171. Rohner A, Spilker ME, Lam JL, et al. Effective targeting of hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. *Mol Cancer Ther*. 2012;11(1):57–65.

172. Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. *Proc Natl Acad Sci U S A*. 2012;109(20):7859–7864.
173. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med.* 2009;361(12):1173–1178.

174. Fulda S. Molecular targeted therapies for rhabdomyosarcoma: focus on hedgehog and apoptosis signaling. *Klinische Padiatrie.* 2013;225(3):115–119.

175. Diersks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemia stem cells is dependent on hedgehog pathway activation. *Cancer Cell.* 2008;14(3):238–249.

176. Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. *Cancer Cell.* 2009;15(2):135–147.

177. Hofmann I, Stover EH, Cullen DE, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. *Cell Stem Cell.* 2009;4(6):559–567.

178. Gao J, Graves S, Koch U, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. *Cell Stem Cell.* 2009;4(6):548–558.

179. Siggins SL, Nguyen NY, McCormack MP, et al. The hedgehog receptor patched1 regulates myeloid and lymphoid progenitors by distinct cell-extrinsic mechanisms. *Blood.* 2009;114(5):995–1004.

180. Merchant A, Joseph G, Wang Q, Brennan S, Matsu W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. *Blood.* 2010;115(12):2391–2396.

181. Reya T, Morrison SJ, Cullen DE, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. *Cancer Res.* 2012;72(19):5048–5059.

182. Domingo-Domenech J, Vidal SJ, Rodriguez-Brado V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. *Cancer Cell.* 2012;22(3):373–388.

183. Takahashi T, Kawakami K, Mishima S, et al. Cycloamine induces eosinophilic differentiation and upregulates CD44 expression in myeloid leukemia cells. *Leuk Res.* 2011;35(5):638–645.

184. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. *Cancer Res.* 2007;67(3):1030–1037.

185. Visbal AP, LaMarca HL, Villamueva E, et al. Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated smoothened. *Dev Biol.* 2011;352(1):116–127.

186. Bar EE, Chaudhry A, Lin A, et al. Cycloamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. *Stem Cells.* 2007;25(10):2524–2533.

187. Clement V, Sanchez P, de Triboulet N, Radovanic I, Ruiz i Altaba A. Hedgehog-Gli1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. *Curr Biol.* 2007;17(2):165–172.

188. Su W, Meng F, Huang L, Zheng M, Liu W, Sun H. Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling. *Exp Hematol.* 2012;40(5):418–427.

189. Visbal AP, LaMarca HL, Villamueva E, et al. Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated smoothened. *Dev Biol.* 2011;352(1):116–127.

190. Bar EE, Chaudhry A, Lin A, et al. Cycloamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. *Stem Cells.* 2007;25(10):2524–2533.

191. Bar EE, Chaudhry A, Lin A, et al. Cycloamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. *Stem Cells.* 2007;25(10):2524–2533.